Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.

Hui Yu,Zhanli Wang,Liangren Zhang,Jufeng Zhang,Qian Huang

DOI: https://doi.org/10.1016/j.bmcl.2007.01.089

IF: 2.94

2007-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Three-dimensional pharmacophore hypothesis was built. The model was then employed as 3D search query to screen the database for other potential lead compounds.

What problem does this paper attempt to address?

Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors

Xu Dan,Sun Haopeng,Chen Yadong,Sun Liping,You Qidong

DOI: https://doi.org/10.1002/cjoc.201190208

2011-01-01

Abstract:A novel ligand-based pharmacophore model for KDR kinase was generated on the basis of chemical features of 30 KDR kinase inhibitors. This pharmacophore model consists of one hydrogen-bond acceptor, one hydrogen-bond donor and two hydrophobic groups. Several methods have been used to validate the model, suggesting that it can serve as a reliable tool for virtual screening to facilitate the discovery of novel KDR inhibitors. The model was then used as database search query from the National Cancer Institute (NCI) database for the rational design to identify new hit compound.
Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.

Hui-Yuan Wang,Zhi-Xing Cao,Lin-Li Li,Pei-Du Jiang,Ying-Lan Zhao,Shi-Dong Luo,Li Yang,Yu-Quan Wei,Sheng-Yong Yang

DOI: https://doi.org/10.1016/j.bmcl.2008.08.033

IF: 2.94

2008-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Pharmacophore model of PLK1 inhibitors was established. This model was then used as a 3D query to screen several chemical databases including Specs, NCI, Maybridge, and CNPD.
The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

Hui Yu,Zhanli Wang,Liangren Zhang,Jufeng Zhang,Qian Huang

DOI: https://doi.org/10.1111/j.1747-0285.2007.00488.x

2007-01-01

Chemical Biology & Drug Design

Abstract:We have applied pharmacophore generation, database searching and docking methodologies to discover new structures for the design of vascular endothelial growth factor receptors, the tyrosine kinase insert domain-containing receptor kinase inhibitors. The chemical function based pharmacophore models were built for kinase insert domain-containing receptor kinase inhibitors from a set of 10 known inhibitors using the algorithm HipHop, which is implemented in the CATALYST software. The highest scoring HipHop model consists of four features: one hydrophobic, one hydrogen bond acceptor, one hydrogen bond donor and one ring aromatic function. Using the algorithm CatShape within CATALYST, the bound conformation of 4-amino-furo [2, 3-d] pyrimidine binding to kinase insert domain-containing receptor kinase was used to generate a shape query. A merged shape and hypothesis query that is in an appropriate alignment was then built. The combined shape and hypothesis model was used as a query to search Maybridge database for other potential lead compounds. A total of 39 compounds were retrieved as hits. The hits obtained were docked into kinase insert domain-containing receptor kinase active site. One novel potential lead was proposed based on CATALYST fit value, LigandFit docking scores, and examination of how the hit retain key interactions known to be required for kinase binding. This compound inhibited vascular endothelial growth factor stimulated kinase insert domain-containing receptor phosphorylation in human umbilical vein endothelial cells.
Pharmacophore Modeling and Virtual Screening to Identify Potential RET Kinase Inhibitors.

Kuei-Chung Shih,Chung-Wai Shiau,Ting-Shou Chen,Ching-Huai Ko,Chih-Lung Lin,Chun-Yuan Lin,Chrong-Shiong Hwang,Chuan-Yi Tang,Wan-Ru Chen,Jui-Wen Huang

DOI: https://doi.org/10.1016/j.bmcl.2011.06.003

IF: 2.94

2011-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Chemical features based 3D pharmacophore model for REarranged during Transfection (RET) tyrosine kinase were developed by using a training set of 26 structurally diverse known RET inhibitors. The best pharmacophore hypothesis, which identified inhibitors with an associated correlation coefficient of 0.90 between their experimental and estimated anti-RET values, contained one hydrogen-bond acceptor, one hydrogen-bond donor, one hydrophobic, and one ring aromatic features. The model was further validated by a testing set, Fischer's randomization test, and goodness of hit (GH) test. We applied this pharmacophore model to screen NCI database for potential RET inhibitors. The hits were docked to RET with GOLD and CDOCKER after filtering by Lipinski's rules. Ultimately, 24 molecules were selected as potential RET inhibitors for further investigation.
Pharmacophore Modeling Study Based on Known Spleen Tyrosine Kinase Inhibitors Together with Virtual Screening for Identifying Novel Inhibitors.

Huan-Zhang Xie,Li,Ji-Xia Ren,Jun Zou,Li Yang,Yu-Quan Wei,Sheng-Yong Yang

DOI: https://doi.org/10.1016/j.bmcl.2009.02.049

IF: 2.94

2009-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:In this investigation, chemical features based 3D pharmacophore models were developed based on the known inhibitors of Spleen tyrosine kinase (Syk) with the aid of hiphop and hyporefine modules within catalyst. The best quantitative pharmacophore model, Hypo1, was used as a 3D structural query for retrieving potential inhibitors from chemical databases including Specs, NCI, MayBridge, and Chinese Nature Product Database (CNPD). The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking studies to refine the retrieved hits. Finally 30 compounds were selected from the top ranked hit compounds and conducted an in vitro kinase inhibitory assay. Six compounds showed a good inhibitory potency against Syk, which have been selected for further investigation.
Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Yiping Li,Yawen Wang,Fuqiang Zhang

DOI: https://doi.org/10.1007/s00894-010-0659-y

IF: 2.172

2010-01-01

Journal of Molecular Modeling

Abstract:Pharmacophore modeling studies were undertaken for a series of compounds belonging several groups of phosphoinositide 3-kinase (PI3K) p110alpha inhibitors: 4-morpholino-2-phenylquinazolines derivatives, pyrido[3',2':4,5]furo-[3,2-d]pyrimidine derivatives, imidazo[1,2-a]pyridine derivatives, sulfonylhydrazone substituted imidazo[1,2-a]pyridines, and LY294002. A five-point pharmacophore with three hydrogen bond acceptors (A), one hydrophobic group (H), and one aromatic ring (R) as pharmacophore features was developed. The pharmacophore hypothesis yielded a statistically significant 3D-QSAR model, with a correlation coefficient of R (2) = 0.95 for training set compounds. The model generated showed excellent predictive power, with a correlation coefficient of Q (2) = 0.88 and r (pret) (2) = 0.95 for a test set of 14 compounds. Furthermore, the structure-activity relationships of PI3K p110alpha inhibitors were elucidated and the activity differences between them discussed. Docking studies were also carried out wherein active and inactive compounds were docked into the active site of the PI3K p110alpha crystal structure to analyze PI3K p110alpha-inhibitor interactions. The results provide insights that will aid optimization of these classes of PI3K p110alpha inhibitors for better activity, and may prove helpful for further lead optimization and virtual screening.
Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Hao-Peng Sun,Jia Zhu,Fei-Hong Chen,Qi-Dong You

DOI: https://doi.org/10.1002/minf.201000178

IF: 4.05

2011-01-01

Molecular Informatics

Abstract:Protein kinase CK2, a member of the serine/threonine kinase family, is an attractive therapeutic target for anticancer combination therapy. A multiple structure-based modeling approach complemented with shape components was taken to build a reliable pharmacophore model for ATP-competitive CK2 inhibitors. The final model consisted of one hydrogen bond acceptor (HBA), one hydrogen bond donor (HBD), two hydrophobic (HY) features, several excluded volumes and shape constraints. In the validation study, this model yielded an enrichment factor of 10.22 and performed fairly well in distinguishing active compounds. SPECS database was searched based on this query and sixteen compounds were retained after multiple filtrations for biological test. 4 compounds with IC50 values less than 10 mu M were disclosed, providing 2 new chemical scaffolds as CK2 inhibitors. It is expected that the information provided here is helpful for discovering more potential CK2 inhibitors.
Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors

Yiping Li,Yawen Wang,Fuqiang Zhang

DOI: https://doi.org/10.1007/s00894-010-0659-y

IF: 2.172

2010-01-01

Journal of Molecular Modeling

Abstract:Pharmacophore modeling studies were undertaken for a series of compounds belonging several groups of phosphoinositide 3-kinase (PI3K) p110α inhibitors: 4-morpholino-2-phenylquinazolines derivatives, pyrido[3′,2′:4,5]furo-[3,2-d]pyrimidine derivatives, imidazo[1,2-a]pyridine derivatives, sulfonylhydrazone substituted imidazo[1,2-a]pyridines, and LY294002. A five-point pharmacophore with three hydrogen bond acceptors (A), one hydrophobic group (H), and one aromatic ring (R) as pharmacophore features was developed. The pharmacophore hypothesis yielded a statistically significant 3D-QSAR model, with a correlation coefficient of R 2 = 0.95 for training set compounds. The model generated showed excellent predictive power, with a correlation coefficient of Q 2 = 0.88 and r pret 2 = 0.95 for a test set of 14 compounds. Furthermore, the structure–activity relationships of PI3K p110α inhibitors were elucidated and the activity differences between them discussed. Docking studies were also carried out wherein active and inactive compounds were docked into the active site of the PI3K p110α crystal structure to analyze PI3K p110α–inhibitor interactions. The results provide insights that will aid optimization of these classes of PI3K p110α inhibitors for better activity, and may prove helpful for further lead optimization and virtual screening.
Pharmacophore Identification of Raf-1 Kinase Inhibitors.

Tian Zhu,Yu Jiao,Ya-Dong Chen,Xuan Wang,Hui-Fang Li,Lu-Yong Zhang,Tao Lu

DOI: https://doi.org/10.1016/j.bmcl.2008.02.068

IF: 2.94

2008-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A three-dimensional pharmacophore model was developed based on 25 currently available Raf-1 kinase inhibitors. The best pharmacophore hypothesis (Hypo1), consisting of four chemical features (one hydrogen-bond acceptor, one hydrogen-bond donor, and two hydrophobic groups), has a correlation coefficient of 0.972. The results of our study provide a valuable tool in designing new leads with desired biological activity by virtual screening.
Pharmacophore Models Generation by Catalyst and Phase Consensus-Based Virtual Screening Protocol Against PI3Kα Inhibitors

Fengxiao Wang,Yadong Chen

DOI: https://doi.org/10.1080/08927022.2012.751592

2013-01-01

Molecular Simulation

Abstract:Phosphoinositide 3-kinases (PI3Ks) family has emerged as promising targets for novel therapeutic agents against neoplastic diseases. Pharmacophore and 3D-quantitative structure–activity relationship modelling were applied to study the structure–activity relationship of PI3K inhibitors. The best HypoGen pharmacophore hypothesis Hypo1 with a correlation coefficient of 0.961 consists of one hydrogen-bond acceptor, one hydrogen-bond donor and two hydrophobic features, whereas the best phase hypothesis AADRRR.378 with favourable statistics (q2 = 0.7368, r2 = 0.9863) has two hydrogen-bond acceptors, one hydrogen-bond donor and three ring aromatic features. Multiple methods, such as Fischer validation, molecular docking and mapping of test set molecules, were carried out to validate these pharmacophore models. Furthermore, a comparative molecular similarity indices analysis candidate hypothesis model was generated as a supplement of pharmacophore hypothesis. Detailed protein–ligand binding information obtained by Glide was utilised in compound optimisation and virtual screening. A molecular database of 133 known inhibitors and 6179 decoys was built for a screening test to quantitatively analyse various hypotheses and scoring parameters. Finally, we designed a workflow integrating HypoGen pharmacophore searching, phase pharmacophore searching and molecular docking for screening the database. With an improved criterion of enrichment factor (EF = 17.43) and ROC curve (AUC = 0.946), this workflow would provide us an original method for novel PI3K inhibitors.
Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.

Huan-Zhang Xie,Ling-Yun Liu,Ji-Xia Ren,Jian-Ping Zhou,Ren-Lin Zheng,Lin-Li Li,Sheng-Yong Yang

DOI: https://doi.org/10.1080/07391102.2011.10507381

2012-01-01

Abstract:IKK2 (I kappa B kinase 2) inhibitors have been identified as potential drug candidates in the treatment of various immune/inflammatory disorders as well as cancer. So far more than one hundred small molecule inhibitors against IKK2 have been reported publicly. In this investigation, pharmacophore modeling was carried out to clarify the essential structure activity relationship for the known IKK2 inhibitors. One of the established pharmacophore hypotheses, namely Hypo8, which has the best prediction ability to an external test data set, was suggested as a template for virtual screening. Evaluation of the performances of Hypo8 and a hybrid method (Hypo8 + docking) in virtual screening indicated that the use of the hybrid virtual screening considerably increased the hit rate and enrichment factor. The hybrid method was therefore adopted for screening several commercially available chemical databases, including Specs, NCI, Maybridge and Chinese Nature Product Database (CNPD), for novel potent IKK2 inhibitors. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five. Finally some of the final hit compounds were selected and suggested for further experimental investigations.
De novo design of N -(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction

Yanmin Zhang,Haichun Liu,Yu Jiao,Haoliang Yuan,Fengxiao Wang,Shuai Lu,Sihui Yao,Zhipeng Ke,Wenting Tai,Yulei Jiang,Yadong Chen,Tao Lu

DOI: https://doi.org/10.1007/s11030-012-9405-y

2012-01-01

Molecular Diversity

Abstract:Vascular endothelial growth factor (VEGF) and its receptor tyrosine kinase VEGFR-2 or kinase insert domain receptor (KDR) have been identified as promising targets for novel anticancer agents. To achieve new potent inhibitors of KDR, we conducted molecular fragment replacement (MFR) studies for the understanding of 3D-QSAR modeling and the docking investigation of arylphthalazines and 2-((1 H -Azol-1-yl)methyl)- N -arylbenzamides-based KDR inhibitors. Two favorable 3D-QSAR models (CoMFA with q 2 , 0.671; r 2 , 0.969; CoMSIA with q 2 , 0.608; r 2 , 0.936) have been developed to predict the biological activity of new compounds. The new molecular database generated by MFR was virtually screened using Glide (docking) and further evaluated with CoMFA prediction, protein–ligand interaction fingerprint (PLIF) and ADMET analysis. 44 N -(pyridin-4-ylmethyl)aniline derivatives as novel potential KDR inhibitors were finally obtained. In this paper, the work flow developed could be applied to de novo drug design and virtual screening potential KDR inhibitors, and use hit compounds to further optimize and design new potential KDR inhibitors.
Pharmacophore Modeling and Virtual Screening Studies of Checkpoint Kinase 1 Inhibitors.

Jin-Juan Chen,Ting-Lin Liu,Li-Jun Yang,Li,Yu-Quan Wei,Sheng-Yong Yang

DOI: https://doi.org/10.1248/cpb.57.704

2009-01-01

Abstract:In this study, chemical feature-based 3-dimensional (3D) pharmacophore models of Checkpoint kinase 1 (Chk1) inhibitors were developed based on the known inhibitors of Chk1. The best pharmacophore model Hypo1 was characterized by the best correlation coefficient (0.9577), and the lowest root mean square deviation (0.8871). Hypo1 consists of one hydrogen-bond acceptor, one hydrogen-bond donor, and two hydrophobic features, as well as one excluded volume. This pharmacophore model was further validated by both test set and cross validation methods. A comparison analysis of Hypo1 with chemical features in the active site of Chk1 indicates that the pharmacophore model Hypo1 can correctly reflect the interactions between Chk1 and its ligands. Then Hypo1 was used to screen chemical databases, including Specs and Chinese Nature Product Database (CNPD) for potential lead compounds. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking study to refine the retrieved hits. Finally some of the most potent (estimated) compounds were selected from the final refined hits and suggested for further experimental investigation.
Combined Pharmacophore Models As Virtual Screening Protocol Against BRD4(1) Inhibitor

Yifei Yang,Fangxia Zou,Leilei Zhao,Yulan Cheng,Xiaoming Zha,Huibin Zhang,Jinpei Zhou

DOI: https://doi.org/10.1007/s00044-016-1513-2

2016-01-01

Medicinal Chemistry Research

Abstract:Bromodomain-containing protein is involved in many essential cellular processes, such as chromosomes for cell cycle progression, cellular viability and embryonic stem cell regulation, which plays a significant role in cancers and lysine acetylation. However, there is no information available regarding the discovery for structurally novel existing BRD4(1) inhibitors up to date. Therefore, we collected reported compounds from GSK library to generate ligand-based pharmacophore and used 11 BRD4(1)-inhibitor co-crystal structures to establish our structure-based pharmacophore for multiple virtual screening of potent BRD4(1) inhibitors. These results may provide important information for further design and optimization of novel BRD4(1) inhibitors in cancer treatment. The results of this study will not only provide a better understanding of BRD4(1) inhibitors interaction, but will also assist the development of new potent hits for BRD4(1).
Pharmacophore Identification, Docking and "in Silico" Screening for Novel Cdk1 Inhibitors

Xiaowu Dong,Jingying Yan,Lilin Du,Peng Wu,Shufang Huang,Tao Liu,Yongzhou Hu

DOI: https://doi.org/10.1016/j.jmgm.2012.04.003

2012-01-01

Abstract:Pharmacophore models of cyclin-dependent kinase-1 (CDK1) inhibitors were established by using the Catalyst/HypoGen. The best pharmacophore model, Hypo1, consists of one hydrogen bond acceptor (HBA), one hydrogen bond donor (HBD), one hydrophobic (HY) and one ring aromatic (RA) feature. The validation results of Hypo1 through cost analysis, test set prediction, Fisher's cross method and receiver operating characteristic (ROC) study indicated that the Hypo1 was statistically valuable and reliable in identifying structural diverse CDK1 inhibitors. It is further supported by the consistent results from molecular docking studies. Finally, the Hypo1 was used to “in silico” screen the NCI and MayBridge database. The preferable hits obtained were further docked into ATP binding site of CDK1, and nine promising compounds were retrieved as novel potential CDK1 inhibitors for further studies.
Towards More Accurate Pharmacophore Modeling: Multicomplex-based Comprehensive Pharmacophore Map and Most-Frequent-feature Pharmacophore Model of CDK2.

Jun Zou,Huan-Zhang Xie,Sheng-Yong Yang,Jin-Juan Chen,Ji-Xia Ren,Yu-Quan Wei

DOI: https://doi.org/10.1016/j.jmgm.2008.07.004

IF: 2.942

2008-01-01

Journal of Molecular Graphics and Modelling

Abstract:Pharmacophore modeling, including ligand- and structure-based approaches, has become an important tool in drug discovery. However, the ligand-based method often strongly depends on the training set selection, and the structure-based pharmacophore model is usually created based on apo structures or a single protein–ligand complex, which might miss some important information. In this study, multicomplex-based method has been suggested to generate a comprehensive pharmacophore map of cyclin-dependent kinase 2 (CDK2) based on a collection of 124 crystal structures of human CDK2–inhibitor complex. Our multicomplex-based comprehensive pharmacophore map contains almost all the chemical features important for CDK2–inhibitor interactions. A comparison with previously reported ligand-based pharmacophores has revealed that the ligand-based models are just a subset of our comprehensive map. Furthermore, one most-frequent-feature pharmacophore model consisting of the most frequent pharmacophore features was constructed based on the statistical frequency information provided by the comprehensive map. Validations to the most-frequent-feature model show that it can not only successfully discriminate between known CDK2 inhibitors and the molecules of focused inactive dataset, but also is capable of correctly predicting the activities of a wide variety of CDK2 inhibitors in an external active dataset. Obviously, this investigation provides some new ideas about how to develop a multicomplex-based pharmacophore model that can be used in virtual screening to discover novel potential lead compounds.
Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.

Hui-Fang Li,Tao Lu,Tian Zhu,Yong-Jun Jiang,Sha-Sha Rao,Li-Ye Hu,Bo-Tao Xin,Ya-Dong Chen

DOI: https://doi.org/10.1016/j.ejmech.2008.09.016

IF: 7.088

2009-01-01

European Journal of Medicinal Chemistry

Abstract:A three-dimensional (3D) quantitative pharmacophore model was developed from a training set of structurally diverse substituted ureas against Raf-1 kinase, which was well validated to be highly predictive by two methods, namely, test set prediction and Cat-Scramble method. Then a virtual database searching was performed with the pharmacophore model as a 3D query, and the bioactivities of the retrieved hits were predicted by the pharmacophore. Subsequently, molecular docking was carried out on the selected hits whose estimated IC50 was less than 1μM. Finally, 29 hits were identified as potential leads against Raf-1 kinase, which exhibited good estimated activities, high docking scores, similar binding mode to experimentally proven compounds and favorable drug-like properties. The study may facilitate the discovery and rational design of novel leads with potent inhibitory activity targeting Raf-1 kinase.
3D QSAR Pharmacophore Modeling for C-Met Kinase Inhibitors

Dandan Huang,Xiaoyun Zhu,Chunlei Tang,Yicheng Mei,Wei Chen,Baowei Yang,Jing Han,Hai Qian,Wenlong Huang

DOI: https://doi.org/10.2174/1573406411208061117

2012-01-01

Medicinal Chemistry

Abstract:The receptor tyrosine kinase c-Met has multiple roles during cancer development and is currently considered as a promising target for cancer therapies. Pharmacophore models of c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio program package. The best quantitative pharmacophore model, Hypo 1, which had the highest correlation coefficient (0.9623), consists of two hydrogen bond acceptors, one hydrophobic feature and two excluded volumes. Then best model was validated by test set prediction, Fischer randomization and decoy set. Besides, the features of Hypo1 were verified to correctly reflect the interactions between kinase active site and its ligands by comparison and superimposition of Hypo 1 in active site of c-Met kinase. The results shows that Hypo 1 has strong capability to identify c-Met kinase inhibitors and to predict the activities of structurally diverse molecules. Therefore, our pharmacophore models were considered as valuable tools for the discovery and development of specific c-Met kinase inhibitors.
Pharmacophore identification of KSP inhibitors.

Fei Liu,Qi-Dong You,Ya-Dong Chen

DOI: https://doi.org/10.1016/j.bmcl.2006.10.083

IF: 2.94

2007-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A three-dimensional pharmacophore model was developed based on 25 currently available KSP inhibitors in Catalyst software package.
Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it.

Hao-Peng Sun,Jia Zhu,Fei-Hong Chen,Sheng-Lie Zhang,Yuan Zhang,Qi-Dong You

DOI: https://doi.org/10.1016/j.ejmech.2011.05.066

IF: 7.088

2011-01-01

European Journal of Medicinal Chemistry

Abstract:IκB kinase β (IKKβ) is an important anti-cancer target that plays crucial role in activating the transcription factor NF-κB in response to various inflammatory stimuli. In order to discover novel IKKβ inhibitors, a 3D chemical-feature-based QSAR pharmacophore model was established. A homology model of IKKβ enzyme was also developed to study the binding mode of IKKβ and its inhibitors. The two models were consistent in predicting the binding conformation of IKKβ inhibitor. Based on the virtual screening using the pharmacophore model, 16 compounds from SPECS database were selected after multiple filtrations for biological test. Two compounds with IC50 values lower than 10 μM were discovered.

Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.

Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors

Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

Pharmacophore Modeling and Virtual Screening to Identify Potential RET Kinase Inhibitors.

Pharmacophore Modeling Study Based on Known Spleen Tyrosine Kinase Inhibitors Together with Virtual Screening for Identifying Novel Inhibitors.

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors

Pharmacophore Identification of Raf-1 Kinase Inhibitors.

Pharmacophore Models Generation by Catalyst and Phase Consensus-Based Virtual Screening Protocol Against PI3Kα Inhibitors

Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.

De novo design of N -(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction

Pharmacophore Modeling and Virtual Screening Studies of Checkpoint Kinase 1 Inhibitors.

Combined Pharmacophore Models As Virtual Screening Protocol Against BRD4(1) Inhibitor

Pharmacophore Identification, Docking and "in Silico" Screening for Novel Cdk1 Inhibitors

Towards More Accurate Pharmacophore Modeling: Multicomplex-based Comprehensive Pharmacophore Map and Most-Frequent-feature Pharmacophore Model of CDK2.

Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.

3D QSAR Pharmacophore Modeling for C-Met Kinase Inhibitors

Pharmacophore identification of KSP inhibitors.

Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it.